The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Are The Forecasted Market Size Figures For The Injectable Targeted Therapy Market In 2026 And 2030?
The injectable targeted therapy market has experienced swift expansion recently. It will grow from $64.22 billion in 2025 to $71.03 billion in 2026 at a compound annual growth rate (CAGR) of 10.6%. This historical growth can be attributed to factors such as rising cancer incidence rates, advancements in monoclonal antibody development, increasing adoption of biologic therapies, the expansion of oncology treatment centers, and enhanced clinical research activity in targeted drugs.
The injectable targeted therapy market is anticipated to experience substantial growth over the next few years, with its size projected to reach **$105.2 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 10.3%.** This expansion during the forecast period is primarily driven by factors such as the increasing number of approvals for targeted injectable therapies, escalating investments in personalized medicine, an expansion of biologics manufacturing capacity, a growing focus on immunotherapy development, and a rising demand for precision treatment protocols. Key trends observed during this period include the increasing development of precision oncology injectables, a rising adoption of antibody-based therapeutics, a heightened emphasis on targeted drug delivery systems, the expansion of combination injectable therapies, and an enhanced focus on minimizing off-target toxicity.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28250&type=smp
Which Strategic Drivers Are Supporting The Injectable Targeted Therapy Market Development?
The increasing demand for personalized medicine is projected to stimulate the growth of the injectable targeted therapy market moving forward. Personalized medicine signifies a healthcare approach that tailors prevention, diagnosis, and treatment according to an individual’s genetic, environmental, and lifestyle elements. The rise in personalized medicine is propelled by developments in genomics, which allow for a deeper understanding of individual genetic variations, thereby enabling more precise, targeted treatments that enhance patient outcomes and minimize trial-and-error in therapies. Injectable targeted therapy supports personalized medicine by delivering medications that specifically target a patient’s unique molecular or genetic disease profile, boosting efficacy and reducing side effects. For instance, in February 2024, as per the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA sanctioned 16 new personalized treatments for rare disease patients, an increase from six in 2022. The newly authorized personalized treatments for 2023 also encompassed seven cancer drugs and three for other diseases and conditions. Consequently, the rising demand for personalized medicine is propelling the expansion of the injectable targeted therapy market.
How Are Different Segment Groups Identified Within The Injectable Targeted Therapy Market?
The injectable targeted therapy market covered in this report is segmented –
1) By Type: Monoclonal Antibodies, Small-Molecules, Immunotoxins, Other Types
2) By Mechanism Of Action: Targeted Inhibition of Signal Transduction Pathways, Targeted Delivery Of Cytotoxic Agents, Immunomodulation
3) By Route Of Administration: Intravenous, Subcutaneous, Intramuscular
4) By Application: Oncology, Cardiometabolism, Immunology, Infectious Diseases, Neuroscience, Ophthalmology, Other Applications
5) By End User: Hospitals, Specialty Clinics, Research Laboratories
Subsegments:
1) By Monoclonal Antibodies: Fully Human Antibodies, Humanized Antibodies, Chimeric Antibodies
2) By Small-Molecules: Tyrosine Kinase Inhibitors, Proteasome Inhibitors, Mtor Inhibitors
3) By Immunotoxins: Recombinant Immunotoxins, Chemical Conjugates, Fusion Proteins
4) By Other Types: Antibody-Drug Conjugates, Bispecific Antibodies, Peptide-Based Therapeutics
Which Trends Are Expected To Shape The Injectable Targeted Therapy Market?
Leading companies in the injectable targeted therapy market are focusing on creating advanced solutions, such as subcutaneous injections, to enhance drug delivery efficiency, improve patient adherence, and more effectively target specific disease pathways. A subcutaneous injection involves delivering medication beneath the skin into the fatty tissue, allowing the drug to be slowly absorbed into the bloodstream. For instance, in August 2025, Eisai Co., Ltd., a pharmaceutical company from Japan, partnered with Biogen Inc., a biotechnology firm from the US, to receive FDA approval for LEQEMBI IQLIK, a treatment for early Alzheimer’s disease. This convenient, once-weekly subcutaneous injection is for the maintenance treatment of early Alzheimer’s disease, enabling patients to self-administer it at home after their initial intravenous therapy. It works by slowing cognitive decline through targeting and clearing amyloid beta plaques and protofibrils, which are primary contributors to Alzheimer’s progression. This formulation reduces the overall treatment time, minimizes systemic side effects compared to IV infusions, and decreases the frequency of infusion center visits, thereby providing greater independence for patients and their care partners.
Which Companies Are Engaged In The Injectable Targeted Therapy Market Environment?
Major companies operating in the injectable targeted therapy market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA, Novartis AG, AstraZeneca plc, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Eisai Co. Ltd., Genentech Inc., Beigene Ltd., Agenus Inc., Xilio Therapeutics Inc.
Access The Complete Injectable Targeted Therapy Market Report:
https://www.thebusinessresearchcompany.com/report/injectable-targeted-therapy-global-market-report
Which Region Accounts For The Highest Share Of The Injectable Targeted Therapy Market?
North America was the largest region in the injectable targeted therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the injectable targeted therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Injectable Targeted Therapy Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=28250&type=smp
Browse Through More Reports Similar to the Global Injectable Targeted Therapy Market 2026, By The Business Research Company
Targeted Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report
Patient Controlled Injectors Market Report 2026
https://www.thebusinessresearchcompany.com/report/patient-controlled-injectors-global-market-report
Injectable Drug Delivery Devices Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model